Nabriva Therapeutics plc (NBRVF)
OTCMKTS · Delayed Price · Currency is USD
0.0001
0.00 (0.00%)
At close: Oct 15, 2025
Nabriva Therapeutics Revenue
Nabriva Therapeutics had revenue of $2.24M in the quarter ending June 30, 2023, a decrease of -75.60%. This brings the company's revenue in the last twelve months to $29.56M, down -16.35% year-over-year. In the year 2022, Nabriva Therapeutics had annual revenue of $36.94M with 27.82% growth.
Revenue (ttm)
29.56M
Revenue Growth
-16.35%
P/S Ratio
0.00
Revenue / Employee
757.87K
Employees
39
Market Cap
323.00
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2022 | 36.94M | 8.04M | 27.82% |
| Dec 31, 2021 | 28.90M | 23.87M | 474.80% |
| Dec 31, 2020 | 5.03M | -4.45M | -46.98% |
| Dec 31, 2019 | 9.48M | -175.00K | -1.81% |
| Dec 31, 2018 | 9.66M | 4.34M | 81.54% |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2014 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2013 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| American Oncology Network | 1.76B |
| Veradigm | 588.02M |
| Jushi Holdings | 256.36M |
| Glass House Brands | 221.55M |
| Elite Pharmaceuticals | 105.45M |
| Silence Therapeutics | 27.17M |
| Nuo Therapeutics | 1.95M |
| Northwest Biotherapeutics | 1.09M |